CHUN-CHAO CHUANG2026-10-162026-10-162023-12-01Pure ID: 15267087Pure UUID: 71b6a5c3-2c3a-476f-8347-c382d94bf68810.1007/s11060-023-04503-3https://www.scopus.com/pages/publications/85178929553https://scholars.csmu.edu.tw/handle/123456789/22729Background: Glioma is a challenging malignant tumor with a low survival rate and no effective treatment. Recently, ganciclovir, an antiviral drug, combined with gene therapy and its own antiviral ability, has been proposed as a potential treatment for glioma. However, there are differences in the results of various clinical trials. In this study, we conducted a systematic review and meta-analysis to evaluate the efficacy of ganciclovir in treating glioma. Methods: We searched databases such as PubMed, EMBASE, and Cochrane Library before March 30, 2023. The search terms included glioma, ganciclovir, valganciclovir and treatment. Calculated 1, 2 and 4-year survival rate by risk difference (RD), and overall survival (OS) by odds ratio (OR). Results: Five randomized controlled trials (RCTs) with a total of 606 high-grade glioma patients were included. The results showed that ganciclovir can improve 2-yeaer (RD = 0.179, 95% CI 0.012–0.346, P = 0.036) and 4-year survival rate (RD = 0.185, 95% CI 0.069–0.3, P = 0.002) and OS (OR 2.393, 95% CI 1.212–4.728, P = 0.012) compared with the control group. Conclusions: This meta-analysis showed that ganciclovir significantly improved the prognosis of glioma patients. Therefore, we suggest that more cases of ganciclovir as a glioma treatment can be conducted, or a large clinical trial can be designed.13enjournal article